secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021244
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics Q1 net loss $22.3M; cash $109.4M funds operations into 2027
------------------------------------------------------------------------------

- Net loss of $22.3M for Q1 2023 vs $13.2M in Q1 2022; includes $15.8M restructuring costs.
- Cash, cash equivalents and marketable securities $109.4M as of March 31, 2023.
- Presented initial preclinical data for lead Kv7 candidate ETX-123; IND-enabling studies initiated.
- Phase 1 clinical studies for ETX-123 planned to start in first half of 2024.
- R&D expenses $5.7M, G&A expenses $17.7M (includes $14.0M restructuring costs).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/0000950170-23-021244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/elym-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer